VM-02 for Vaginal Hygiene

DG
Overseen ByDirk Gevers
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Seed Health

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how the personal care product VM-02 can enhance vaginal health by boosting beneficial bacteria. Researchers are testing various forms of the product, such as capsules and tablets, and comparing them to a placebo and a commercial competitor. They aim to determine if VM-02 can increase the presence of Lactobacillus crispatus (a beneficial bacterium) and reduce discomfort like odor. Women with regular menstrual cycles who are open to using intra-vaginal products may be suitable candidates for this trial.

As an unphased trial, this study allows participants to contribute to significant research on vaginal health and potentially benefit from innovative care solutions.

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, you must agree not to use certain intra-vaginal products during the study.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that VM-02, a personal care product with prebiotics, postbiotics, and specific strains of Lactobacillus crispatus, is generally safe. Previous studies examined its use as a vaginal suppository and found no major side effects. However, safety information notes that VM-02 might cause eye irritation or allergic reactions if swallowed, so careful use is important.

Lactobacillus crispatus, a type of bacteria naturally found in healthy women, adds to its safety. This bacteria helps maintain a healthy vaginal balance, supporting vaginal health and possibly preventing bacterial vaginosis or yeast infections. Although this trial phase doesn't provide detailed safety data from earlier phases, the use of naturally occurring bacteria suggests it is likely safe.

Overall, while these studies have not reported specific negative effects, the ingredients in VM-02 are generally considered safe for most people when used as directed. Participants considering joining the trial can feel reassured by the lack of significant negative reports and the product's support for natural vaginal health.12345

Why are researchers excited about this trial?

Researchers are excited about these treatments for vaginal health because they're exploring new ways to maintain and improve this vital aspect of women's health. Unlike traditional oral probiotics, the VM-02 treatment includes both suppository capsules and tablets, delivering active ingredients directly to the vaginal area, which could enhance their effectiveness. This direct delivery method is unique and may offer faster and more targeted results compared to standard oral products. Additionally, the study is investigating an oral capsule version, which could provide flexibility and convenience in how the treatment is administered. By testing these varied approaches, researchers aim to find more effective and user-friendly solutions for maintaining vaginal health.

What evidence suggests that this trial's treatments could be effective for improving vaginal health?

Research has shown that probiotics containing Lactobacillus crispatus can improve vaginal health. This bacterium helps maintain a healthy microbial balance in the vagina. Studies on similar products have demonstrated positive effects, such as reducing symptoms of bacterial vaginosis, an infection caused by bacterial imbalance. In this trial, participants may receive the VM-02 product, which combines prebiotics, postbiotics, and specific strains of Lactobacillus crispatus to potentially enhance these benefits. Early findings suggest that these ingredients could increase the number of beneficial bacteria and help control vaginal pH levels, potentially reducing discomfort from odor. While direct evidence for VM-02 is still developing, its ingredients show promise for supporting vaginal health.26789

Are You a Good Fit for This Trial?

Inclusion Criteria

Reproductive age women aged ≥ 18.
History of regular menses every 21-35 days for six months prior to the study.
Agreement not to use specified intra-vaginal products during the study product use.
See 3 more

Exclusion Criteria

Pregnancy or planned pregnancy in the next 6 months.
Two or more amenorrheic months in the past 6 months.
Lives in the state of New York.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the personal care product or placebo according to their assigned arm. The treatment involves vaginal suppository capsules, tablets, or oral capsules administered over two menstrual cycles.

8 weeks
8 virtual check-ins

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments of vaginal microbiome changes and user experience.

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • VM-02
  • VM-02 Placebo
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Vaginal Suppository Tablet ActiveExperimental Treatment1 Intervention
Group II: Vaginal Suppository Capsule ActiveExperimental Treatment1 Intervention
Group III: Oral Capsule ActiveExperimental Treatment1 Intervention
Group IV: Commercial Oral Vaginal Probiotic CompetitorExperimental Treatment1 Intervention
Group V: Vaginal Suppository CapsulePlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Seed Health

Lead Sponsor

Trials
5
Recruited
480+

Published Research Related to This Trial

Adjuvant chemotherapy significantly improves overall survival, disease-specific survival, and disease-free survival in high-risk Stage II colorectal cancer patients, with a hazard ratio of 0.61 for overall survival, based on a meta-analysis of 29 studies involving 183,749 participants.
The benefits of chemotherapy were consistent across various subgroups, including patients with multiple high-risk features and those with colon cancer, indicating that it can be an important treatment option for improving patient outcomes.
Postoperative chemotherapy improves survival in patients with resected high-risk Stage II colorectal cancer: results of a systematic review and meta-analysis.Simillis, C., Singh, HKSI., Afxentiou, T., et al.[2021]
A systematic review of 82 publications on the safety of rhBMP-2 for spinal fusion revealed that the most effective databases for identifying adverse effects data are the Science Citation Index (SCI) and EMBASE, both achieving a sensitivity of 62%.
To comprehensively identify all relevant studies, a combination of multiple sources including SCI, EMBASE, MEDLINE/PubMED, and additional methods like reference checking is necessary, highlighting the complexity of gathering complete safety data for medical devices.
The contribution of different information sources to identify adverse effects of a medical device: a case study using a systematic review of spinal fusion.Golder, S., Wright, K., Rodgers, M.[2018]
The safety of marketed drugs is a significant concern, as some commonly prescribed medications can lead to serious or life-threatening side effects in patients.
The ChEMBL resource will provide a curated drug safety data set, including toxicity classifications and black box warnings, which will be freely available and regularly updated to aid in drug safety research and discovery.
Drug Safety Data Curation and Modeling in ChEMBL: Boxed Warnings and Withdrawn Drugs.Hunter, FMI., Bento, AP., Bosc, N., et al.[2023]

Citations

Randomized, Double-blind, Placebo-controlled Trial ...This trial tests a new personal care product, VM-02, on healthy women to improve vaginal health. The product contains beneficial bacteria and compounds to ...
Drug treatment for oral submucous fibrosis: an update - PMCThe aim of this review is to evaluate the different medicinal interventions available for the management of oral submucous fibrosis (OSF).
Oral itraconazole versus oral voriconazole for treatment- ...The primary outcome was the proportion of participants achieving a favourable response (clinical and radiological stability or improvement) at 6 ...
NCT06452277 | A Study to Learn More About How Well ...The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced ...
Exploratory Study on Efficacy and Safety of Minocycline ...The primary outcome was eradication rates. Secondary outcomes included adverse effects (AEs). Results: As first-line treatment, eradication rates were 96.7% (VA) ...
Study Details | NCT05659745 | Randomized, Double-blind ...A two-arm randomized, double-blind, placebo-controlled study to evaluate VM-02 as a vaginal suppository capsule. Arm #1: Vaginal application of single-use ...
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs...No information is available for this page.
Once daily oral relugolix combination therapy versus ...Eligible patients who completed SPIRIT 1 or 2 could enrol in an 80-week open-label extension study to collect additional efficacy and safety ...
216578Orig1s000 - accessdata.fda.govThe pooled phase 3 studies consist of all randomized individuals who received at least one dose of study drug from the three 52- week phase 3 ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security